



TECHNICAL SPECIFICATIONS POSTING BOOKLET:
Physician Quality Measures
Group Insurance Commission (GIC)
CPII

VERSION 1.0

2008.08.18

CONFIDENTIAL

Resolution Health, Inc. Proprietary Statement: This material constitutes proprietary and trade secret information of Resolution Health. This material may only be used for non-commercial purposes.

TABLE OF CONTENTS

TABLE OF CONTENTS	II
BACKGROUND	1
CARDIAC MEASURES	2
Atrial Fibrillation	2
Atrial Fibrillation 10: warfarin_INR check	2
Misc Disease 1: Amiodarone_TSH baseline	3
Misc Diseases 440: Warfarin_no PT >2 months	4
Heart Failure	5
HF and AF_Warfarin	5
CHF 1: CHF_EF check.....	6
CHF 34: CHF_CCB.....	7
CHF 110: CHF_beta-blocker.....	8
CHF 193: CHF_ACEI or ARB.....	9
Coronary Heart Disease	10
CHD 1: Post MI_ACE inhibitor	10
CHD 94: Post MI_ beta-blocker	11
CHD 259: CHD_statin.....	12
HEDIS: Cholesterol Mgt in CHD	13
Bare Metal Stent_Clopidogrel	14
Drug-Eluting Stent_Clopidogrel.....	15
HEDIS: Beta-Blocker Persistence_Post MI.....	16
Hypertension.....	17
Hypertension 10: HTN_blood glucose	17
Hypertension 11: HTN_potassium	18
Hypertension 12: HTN_lipid panel.....	19
Hypertension 14: HTN_creatinine.....	20
Hypertension 23: HTN_SA-CCB	21
DEPRESSION MEASURES.....	22
Depression_Anti-AnxietyRx.....	22
HEDIS Depression 161: Depression_ 12 wks f/u.....	23
HEDIS Depression 162: New Depression_ < 12 wk Rx	24
HEDIS Depression Rx >180d.....	25
Bipolar Disorder_Antimanic agent.....	26
DERMATOLOGY	27
Lotrisone_Inappropriate Use	27
DRUG SAFETY MEASURES.....	28
HEDIS: PersistACE_ARB_K_SCr_12m.....	28
HEDIS: PersistentDigoxin_K Sc_12m.....	29
HEDIS: PersistDiuretics_K_SCr_12m	30
HEDIS: PersistAnticonvulsants_SerumDrug12m	31
Drug Safety 2: Clozapine_WBC needed	32
Lithium_Annual Creatinine Test	33

Lithium_Annual Thyroid Test	34
Lithium_Annual Lithium Test	35
Prostate 1: BPH_anticholinergic.....	36
MEASURE DESCRIPTION	36
TZD Use_Annual LFT.....	37
ENDOCRINE MEASURES	38
Diabetes.....	38
HEDIS: Diabetes 2: DM_HbA1c.....	38
HEDIS: Diabetes 115 DM_LDL	39
Diabetes 121: DM HTN_ACEI	40
HEDIS: Diabetes 126 DM_proteinuria	41
New DM2_Metformin	42
Dyslipidemia.....	43
Dyslipidemia 55: New Lipid Rx_lipid12wk.....	43
GASTROENTEROLOGY MEASURES.....	44
Misc Disease 2: Arthritis_ChronSAID_UlcerProphy.....	44
GI 1: IBD_Chronic Steroids_BMD test.....	45
GI 2: PUD_Comp_Hpylori_treatment.....	46
MEASURE DESCRIPTION	46
GI 3: PUD_Comp_Hpylori_Test	47
Infectious Disease 1: HIV_Hep B screen	48
MEASURE DESCRIPTION	48
Infectious Disease 2: HIV_Hep C screen	49
MEASURE DESCRIPTION	49
Infectious Disease 3: HepCRx_HCV genotype test	50
Infectious Disease 4: HepCRx_HCV_ViralLoad	51
HBV postvaccination titers.....	52
HEMATOLOGY MEASURES	53
Vascular 1: PE_antithrombotic	53
Vascular 2: LE DVT_antithrombotic.....	54
MENTAL BEHAVIORAL HEALTH	55
HEDIS: Peds ADHD Rx 30d visit.....	55
HEDIS: Peds ADHD Rx 2Visits 31-300d	56
NEUROLOGY	57
Headache 21: CHD_MigraineRxInteraction.....	57
New Dementia_B12 TSH	58
OPHTHALMOLOGY	59
HEDIS: Glaucoma Screening	59
PostOp Comp_Cataract Surgery	60
OTOLARYNGOLOGY	61
Acute Otitis Externa_Systemic Abx	61
Otitis Media Effusion_Systemic Abx	62
Tympanostomy Tube Hearing Test	63
PRENATAL CARE MEASURES	64
Prenatal Care 12: Pregnancy_HIV.....	64

Prenatal Care 11: Pregnancy Screen_ Hep B.....	65
Prenatal Care 38: Diabetes_ Oral agents	66
PREVENTIVE HEALTH MEASURES	67
Women’s Health	67
Preventive Care 26: High-risk_Pap Smear	67
Osteo 1: Women 66-67y_BMDTest	68
HEDIS: CervCA_screen	69
HEDIS: Osteoporosis_Mgmt_Fx.....	70
HEDIS: Chlamydia_screen.....	71
BrCA 8: BrCA_mammogram.....	72
HEDIS: BrCA_Screen	73
Well Child Visits.....	74
Preventative Health 278: Age 0-6mo_ 4 visits	74
Preventative Health 279: Age 6-12mo_ 3 visits	75
Preventative Health 280: Age 12-24m_3 visits	76
Preventative Health 281: Age 2-6yrs_1 visit.....	77
Preventative Health 282: Age 7-18yrs_1 visit.....	78
PULMONARY MEASURES.....	79
Asthma	79
Mod-severe Asthma_ B2 agonist.....	79
HEDIS_Appropriate Meds for Asthma	80
COPD.....	81
Misc Diseases 236: COPD_Asthma_B2 Overuse	81
Other Respiratory.....	82
HEDIS: Pharyngitis Appropriate Testing	82
HEDIS: URI Appropriate Rx.....	83
HEDIS: Acute Bronchitis Adults_Avoid Abx.....	84
RHEUMATOLOGY.....	85
HEDIS: DMARDs in RA.....	85
New RA_ESR or CRP in 3mos	86
RA_New DMARDs Baseline CBC	86
RA_New DMARDs Baseline Scr.....	87
RA_New DMARDs Baseline AST or ALT.....	88
RA_New DMARD Baseline CXR.....	89
Hydroxychloroquine Use_Annual Eye Exam.....	90
Methotrexate_CBC q12 weeks	91
Methotrexate_Cr q12 weeks	92
Methotrexate_LFT q12wks.....	93
Osteoporosis Rx Therapy.....	94

BACKGROUND

This document provides information regarding each of the measures that Resolution Health, Inc. (RHI) currently uses for its physician quality profiling (PQP) activities.

For each quality of care measure, the following information is provided:

Measure Title

This title is used when reporting measure results for providers and plans.

Measure Description

A description of the overall purpose of the measure.

Numerator and Denominator

The numerator includes the proportion of measure-eligible patients whose care appears from available claims data to be consistent with the evidence-based clinical guideline upon which the measure is based. The denominator includes the patient population eligible for the measure.

Applicable Specialties

The clinical specialties mapped to the measure. The specialty mapping for each measure is based upon RHI's determination as to which specialties could reasonably be expected to manage the clinical issue the measure addresses.

RHI attributes a patient observation for a measure to a particular provider if that provider's specialty is mapped to the measure *and* if that provider is considered a "primary specialist" for the patient. For any given patient, the primary specialist for a particular specialty is the physician within that specialty who provided the most ambulatory care services to that patient, as determined by an analysis of the member's prescription claims and medical claims for office visits during the most recent 18 months.

Measure Citation

These include the organization (e.g., American Heart Association) that developed the clinical practice guideline upon which the quality measure is based, as well as citations to key publications related to the measure. We also provide an indication as to whether the measure is based on a HEDIS measure.

CARDIAC MEASURES

Atrial Fibrillation

Atrial Fibrillation 10: warfarin_INR check	
MEASURE DESCRIPTION	This measure identifies patients with atrial fibrillation diagnosed during the measurement year who started warfarin and who had an INR test within 2 weeks after the warfarin start date.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had an INR test within 2 weeks after the warfarin start date</p> <p><u>Denominator</u> = Patients diagnosed with atrial fibrillation newly started on warfarin, excluding those with any ER visit or hospitalization 14 days after the warfarin start date</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	Hirsch J, Fuster V, Ansell J, and Halperin JL. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation. 2003;107:1692-1711.

Misc Disease 1: Amiodarone_TSH baseline	
MEASURE DESCRIPTION	This measure identifies patients who had a TSH baseline measurement at the start of amiodarone therapy.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had TSH baseline measurement within 60 days prior to or 30 days after the start of amiodarone</p> <p><u>Denominator</u> = Adult patients who started amiodarone during the first 11 months of the measurement year, without evidence of total thyroidectomy in the past</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	<p>Siddoway LA. Amiodarone: guidelines for use and monitoring. Am Fam Physician. 2003;68(11):2189-96.</p> <p>Baskin, HJ, Cobin RH, et al; AACE Thyroid Task Force. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Evaluation and Treatment of Hyperthyroidism and Hypothyroidism. Endocrine Practice. 2002;8(6):457-469.</p> <p>Hanja KJ and Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med. 1997;126:63-73.</p>

Misc Diseases 440: Warfarin_no PT >2 months	
MEASURE DESCRIPTION	This measure identifies patients taking warfarin during the measurement year who had at least 1 PT/INR test within 60 days after the earliest detected warfarin prescription.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had a PT/INR test within 60 days after the earliest observed warfarin prescription during the measurement year</p> <p><u>Denominator</u> = Patients who are taking warfarin during the measurement year, excluding those with any ER visit or hospitalization during the 60 days after the earliest observed warfarin prescription during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine
MEASURE CITATION	Hirsch J, Fuster V, Ansell J, and Halperin JL. American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy. Circulation. 2003;107:1692-1711.

Heart Failure

HF and AF_Warfarin	
MEASURE DESCRIPTION	This measure identifies the percentage of adult patients with a history of heart failure prior to the measurement year, who experienced atrial fibrillation during the measurement year, and received a prescription for warfarin (excluding individuals with warfarin contraindications). This rule is based on the AMA-PCPI Heart Failure measure: Warfarin Therapy for Patients with Atrial Fibrillation (HF-8).
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had at least one prescription for warfarin during the measurement year.</p> <p><u>Denominator</u> = Patients with heart failure who were diagnosed with atrial fibrillation during the first 11 months of the measurement year.</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	AMA/PCPI/ACC/AHA-Owned, NQF-Endorsed Cardiovascular Ambulatory Care Performance Measures: Heart Failure (HF-8). Version 3.0, July 2007.

CHF 1: CHF_EF check	
MEASURE DESCRIPTION	This measure identifies patients newly diagnosed with heart failure (HF) in the outpatient setting during the measurement year who had left ventricular ejection fraction (LVEF) evaluated within 30 days after diagnosis.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator with a LVEF measurement (cardiac catheterization, MUGA, etc.) within 30 days of diagnosis</p> <p><u>Denominator</u> = Patients with newly diagnosed HF as an outpatient during the measurement year, excluding those with hospital or ER visits for any reason +/- 30 days after diagnosis of HF</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	<p>Adams KF, et al. Heart Failure Society of America 2006 Comprehensive Heart Failure Practice Guideline. J Cardiac Fail. 2006;12(1):10-38.</p> <p>Hunt SA, Abraham WT, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Bethesda (MD): American College of Cardiology Foundation (ACCF). J Am Coll Cardiol. 2005;46(6):e1-82.</p>

CHF 34: CHF_ CCB	
MEASURE DESCRIPTION	This measure identifies patients with HF who are not taking a short-acting calcium channel blocker (SA-CCB).
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who are not taking a short-acting calcium channel blocker (CCB) during the last 6 months of the measurement year</p> <p><u>Denominator</u> = Patients with HF diagnosed prior to the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	<p>Adams KF, et al. Heart Failure Society of America 2006 Comprehensive Heart Failure Practice Guideline. J Cardiac Fail. 2006;12(1):10-38.</p> <p>Hunt SA, Abraham WT, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Bethesda (MD): American College of Cardiology Foundation (ACCF). J Am Coll Cardiol. 2005;46(6):e1-82.</p>

CHF 110: CHF_beta-blocker	
MEASURE DESCRIPTION	This measure identifies patients with HF prior to the measurement year who are taking beta blockers during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who have at least 1 Rx claim for a beta-blocker during the measurement year</p> <p><u>Denominator</u> = Patients with a diagnosis of HF prior to the measurement year and no contraindication to beta blockers (contraindications include: history of asthma, use of inhaled corticosteroids, hypotension, 2nd- or 3rd-degree heart block, sinus bradycardia, or COPD)</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	<p>Adams KF, et al. Heart Failure Society of America 2006 Comprehensive Heart Failure Practice Guideline. J Cardiac Fail. 2006;12(1):10-38.</p> <p>Hunt SA, Abraham WT, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Bethesda (MD): American College of Cardiology Foundation (ACCF). J Am Coll Cardiol. 2005;46(6):e1-82.</p>

CHF 193: CHF_ACEI or ARB	
MEASURE DESCRIPTION	This measure identifies the percentage of patients with a history of heart failure (HF) prior to the measurement year that have a prescription claim for an ACE inhibitor or Angiotensin Receptor Blocker (ARB) during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator with at least 1 prescription claim for an ACE inhibitor or ARB during the measurement year</p> <p><u>Denominator</u> = Patients with a history of HF diagnosed prior to the measurement year, who do not have a contraindication to ACE/ARB therapy (ACE/ARB contraindications include: hyperkalemia, active pregnancy, renal artery stenosis)</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
LITERATURE REFERENCES	<p>Adams KF, et al Heart Failure Society of America 2006 Comprehensive Heart Failure Practice Guideline. J of Cardiac Failure. 2006; 12(1)</p> <p>Hunt SA, Abraham WT, et. al.. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Bethesda (MD): American College of Cardiology Foundation (ACCF); 2005 Aug. 82 p.</p>

Coronary Heart Disease

CHD 1: Post MI_ACE inhibitor	
MEASURE DESCRIPTION	This measure identifies patients with ST elevation MI (STEMI), or non-ST elevation MI (NSTEMI) plus a history of hypertension, HF and/or diabetes prior to the measurement year who are taking an ACEI or an ARB during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator with at least 1 prescription claim for an ACEI or an ARB during the measurement year</p> <p><u>Denominator</u> = Patients with STEMI, or NSTEMI with hypertension, HF and/or diabetes, prior to the measurement year who do not have a contraindication to ACEI/ARB therapy (contraindications include hyperkalemia, active pregnancy, and renal artery stenosis)</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	<p>Antman EM, Anbe DT, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol. 2004;44:671-719.</p> <p>Braunwald E. ACC/AHA 2002 Guideline Update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the management of patients with unstable angina. J Am Coll Cardiol. 2002;40(7):1366-74.</p>

CHD 94: Post MI_ beta-blocker	
MEASURE DESCRIPTION	This measure identifies patients diagnosed with acute myocardial infarction (AMI) prior to the measurement year who are taking a beta blocker during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who have ≥ 1 Rx claim for a beta blocker during the measurement year</p> <p><u>Denominator</u> = Patients with a diagnosis of AMI prior to the measurement year who do not have a contraindication to beta blockers (contraindications include: history of asthma, presence of inhaled corticosteroids, hypotension, 2nd- or 3rd-degree heart block, sinus bradycardia, or COPD)</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	<p>Antman EM, Anbe DT, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol. 2004;44:671-719.</p> <p>Braunwald E. ACC/AHA 2002 Guideline Update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the management of patients with unstable angina. J Am Coll Cardiol. 2002;40(7):1366-74.</p>

CHD 259: CHD_statin	
MEASURE DESCRIPTION	This measure identifies patients with coronary heart disease who are taking a statin.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had ≥ 1 Rx for a statin medication during the measurement year</p> <p><u>Denominator</u> = Patients with coronary heart disease before the measurement year without a contraindication to statin therapy (contraindications include active pregnancy or chronic liver disease)</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	<p>Braunwald E. ACC/AHA 2002 Guideline Update for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the management of patients with unstable angina. J Am Coll Cardiol. 2002;40(7):1366-74.</p> <p>Snow V, et al. Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med. 2004;141:562-7.</p> <p>National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda (MD): U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung and Blood Institute; 2001.</p>

HEDIS: Cholesterol Mgt in CHD	
MEASURE DESCRIPTION	This measure identifies patients 18-75 years old discharged alive for acute myocardial infarction (AMI), coronary bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) from January 1 to November 1 of the year prior to the measurement year, or who had a diagnosis of ischemic vascular disease (IVD) during or in the year prior to the measurement year, who had a LDL-C check during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had a lipid test within the measurement year</p> <p><u>Denominator</u> = Patients with CHD diagnosed prior to the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	<p>National Committee for Quality Assurance. HEDIS 2008. Vol 2. Washington, DC: National Committee for Quality Assurance; 2007.</p> <p>National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda (MD): U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung and Blood Institute; 2001.</p> <p>Antman EM, Anbe DT, et al. ACC-AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol. 2004;44:671-719.</p>

Bare Metal Stent_Clopidogrel	
MEASURE DESCRIPTION	This measure identifies patients undergoing percutaneous coronary intervention (PCI) with placement of a bare metal intracoronary stent during the first 11 months of the measurement year, who had a prescription for Plavix (clopidogrel) within 30 days after stent placement.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator with a prescription for clopidogrel within 30 days following stent placement</p> <p><u>Denominator</u> = Patients who underwent PCI with placement of a bare metal intracoronary stent, during the first 11 months of the measurement year, excluding those with contraindications to clopidogrel</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	<p>Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). <i>Circulation</i>. 2006 Feb 21;113(7):e166-286.</p> <p>Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. <i>Circulation</i>. 2007;115(6):813-8.</p>

Drug-Eluting Stent_Clopidogrel	
MEASURE DESCRIPTION	This measure identifies patients undergoing percutaneous coronary intervention (PCI) with placement of a drug-eluting intracoronary stent during the first 9 months of the measurement year, who had use of clopidogrel in the 3 months following stent placement.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who filled prescription(s) for clopidogrel in the 3 months following placement of the drug-eluting intracoronary stent</p> <p><u>Denominator</u> = Patients who underwent PCI with placement of a drug-eluting intracoronary stent, during the first 9 months of the measurement year, excluding those with contraindications to clopidogrel</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	<p>Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). <i>Circulation</i>. 2006;113(7):e166-286.</p> <p>Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. <i>Circulation</i>. 2007;115(6):813-8.</p>

HEDIS: Beta-Blocker Persistence_Post MI	
MEASURE DESCRIPTION	This measure identifies patients ages 35 or older who were hospitalized for AMI and discharged from the hospital between July 1 of the year prior to the measurement year and June 30 of the measurement year who have been taking a beta blocker for at least 6 months post discharge.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who were taking a beta blocker for at least 6 months post discharge and have a medication possession ratio during that time of $\geq 75\%$</p> <p><u>Denominator</u> = Patients hospitalized and discharged with an AMI between July 1 of the year prior to the measurement year and June 30 of the measurement year, who do not have a contraindication to beta blockers (contraindications include: history of asthma, use of inhaled corticosteroids, hypotension, 2nd- or 3rd-degree heart block, sinus bradycardia, or COPD)</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Vol 2. Washington, DC: National Committee for Quality Assurance; 2007.

Hypertension

Hypertension 10: HTN_blood glucose	
MEASURE DESCRIPTION	This measure identifies patients with newly diagnosed hypertension during the measurement year with a lab claim for a serum glucose test at the time of diagnosis, if not done in the 6 months prior to diagnosis.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had a serum or plasma glucose test within 30 days after initial diagnosis of hypertension</p> <p><u>Denominator</u> = Patients who meet criteria for newly diagnosed hypertension during the measurement year and who did not have a serum or plasma glucose test in the 6 months prior to diagnosis</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	Chobanian AV, et al. The Seventh Report of the Joint National Committee on prevention, detection, and evaluation and treatment of high blood pressure. NHLBI writing team. 2004. 28-32. NIH Publication No. 04-5230



Hypertension 11: HTN_potassium	
MEASURE DESCRIPTION	This measure identifies patients with newly diagnosed hypertension during the measurement year with a lab claim for a serum potassium test at the time of diagnosis, if not done in the 6 months prior to diagnosis.
NUMERATOR/DENOMINATOR	<u>Numerator</u> = Patients in the denominator who had a serum potassium test within 30 days after initial diagnosis <u>Denominator</u> = Patients who meet criteria for newly diagnosed hypertension during the measurement year and who did not have a serum potassium test in the 6 months prior to diagnosis
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	Chobanian AV, et al. The Seventh Report of the Joint National Committee on prevention, detection, and evaluation and treatment of high blood pressure. NHLBI writing team. 2004. 28-32. NIH Publication No. 04-5230

Hypertension 12: HTN_lipid panel	
MEASURE DESCRIPTION	This measure identifies patients with newly diagnosed hypertension during the measurement year with a lab claim for a serum lipid panel test at the time of diagnosis, if not done in the year prior to diagnosis.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had a lipid panel test within 30 days after initial diagnosis of hypertension</p> <p><u>Denominator</u> = Patients who meet criteria for newly diagnosed hypertension during the measurement year and who did not have a serum lipid panel test in the year prior to diagnosis</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	Chobanian AV, et al. The Seventh Report of the Joint National Committee on prevention, detection, and evaluation and treatment of high blood pressure. NHLBI writing team. 2004. 28-32. NIH Publication No. 04-5230



Hypertension 14: HTN_creatinine	
MEASURE DESCRIPTION	This measure identifies patients with newly diagnosed hypertension during the measurement year with a lab claim for a serum creatinine test at the time of diagnosis, if not done in the 6 months prior to diagnosis.
NUMERATOR/DENOMINATOR	<u>Numerator</u> = Patients in the denominator who had a serum creatinine test within 30 days after initial diagnosis of hypertension <u>Denominator</u> = Patients who meet criteria for newly diagnosed hypertension during the measurement year and who did not have a serum creatinine test in the 6 months prior to diagnosis
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	Chobanian AV, et al. The Seventh Report of the Joint National Committee on prevention, detection, and evaluation and treatment of high blood pressure. NHLBI writing team. 2004. 28-32. NIH Publication No. 04-5230



Hypertension 23: HTN_SA-CCB	
MEASURE DESCRIPTION	This measure identifies patients with hypertension diagnosed before the measurement year who are not taking a short-acting calcium channel blocker.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who are not treated with a SA-CCB during the measurement year</p> <p><u>Denominator</u> = Patients with hypertension diagnosed before the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	<p>Chobanian AV, et al. The Seventh Report of the Joint National Committee on prevention, detection, and evaluation and treatment of high blood pressure. NHLBI writing team. 2004. 28-32. NIH Publication No. 04-5230</p> <p>Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92:1326-1331.</p>

DEPRESSION MEASURES

Depression_Anti-AnxietyRx	
MEASURE DESCRIPTION	This measure identifies patients newly diagnosed with depression during the first 9 months of the measurement year who have not received an anti-anxiety agent as the sole treatment for their depression.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who have not received an anti-anxiety agent as sole treatment for their depression</p> <p><u>Denominator</u> = Patients with newly diagnosed depression during the first 9 months of the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Psychiatry
MEASURE CITATION	Practice guideline for the treatment of patients with major depressive disorder, Second Ed. American Psychiatric Association. April 2000. (rev Feb 2005)

HEDIS Depression 161: Depression_ 12 wks f/u	
MEASURE DESCRIPTION	This measure identifies patients age 18 or older as of April 30 of the measurement year with newly diagnosed depression who started antidepressant therapy and who had at least 3 follow-up visits within 12 weeks after starting treatment.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had at least 3 visits during the first 12 weeks of treatment while on antidepressant medication</p> <p><u>Denominator</u> = Patients with depression, diagnosed between May 1st of the preceding year to April 30th of the measurement year, who started on medication for depression from 30 days before to 14 days after the depression diagnosis date</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Psychiatry
MEASURE CITATION	<p>Practice guideline for the treatment of patients with major depressive disorder, Second Ed. American Psychiatric Association. April 2000. (rev Feb 2005)</p> <p>National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.</p>

HEDIS Depression 162: New Depression < 12 wk Rx	
MEASURE DESCRIPTION	This measure identifies patients with newly diagnosed depression who started an antidepressant, and who were maintained on medication for the recommended 12 weeks of acute phase treatment.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who were maintained on antidepressant therapy for at least 84 days in the 114-day period following start of antidepressant</p> <p><u>Denominator</u> = Patients with depression, diagnosed between May 1st of the preceding year to April 30th of the measurement year, who started on medication for depression from 30 days before to 14 days after the depression diagnosis date</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Psychiatry
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.

HEDIS Depression Rx >180d	
MEASURE DESCRIPTION	This measure identifies patients with newly diagnosed depression who were started on an antidepressant, and who remained on medication for at least 180 days of a 231-day period following the start of an antidepressant.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who remained on medication for at least 180 days of a 231-day period following the start of an antidepressant</p> <p><u>Denominator</u> = Patients with depression, diagnosed between May 1st of the preceding year to April 30th of the measurement year, who started medication for depression at least 180 days prior to the end of the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Psychiatry.
MEASURE CITATION	<p>Practice guideline for the treatment of patients with major depressive disorder, Second Ed. American Psychiatric Association. April 2000. (rev Feb 2005)</p> <p>National Committee for Quality Assurance. HEDIS 2007. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.</p>

Bipolar Disorder_Antimanic agent	
MEASURE DESCRIPTION	This measure identifies the percentage of patients with newly diagnosed bipolar disorder who have received at least 1 prescription for a mood-stabilizing agent during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who have received at least 1 prescription for a mood-stabilizing agent during the measurement year</p> <p><u>Denominator</u> = Patients newly diagnosed as having bipolar disorder earlier than 30 days before the end of the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Psychiatry
LITERATURE REFERENCES	<p>Chou JC, Fazzio L. Maintenance treatment of bipolar disorder: Applying research to clinical practice. J Psychiatr Pract. 2006 Sep;12(5):283-99</p> <p>American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002 Apr;159(4 Suppl):1-50.</p>

DERMATOLOGY

Lotrisone_Inappropriate Use	
MEASURE DESCRIPTION	This measure identifies the percentage of pediatric (<18 years of age) patients diagnosed with tinea infection during the measurement year who are not receiving steroid and antifungal combination drug (e.g., Lotrisone) in the 30 days following diagnosis.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who were not prescribed a steroid and antifungal combination medication (e.g. Lotrisone) within 30 days after diagnosis</p> <p><u>Denominator</u> = Pediatric patients diagnosed with tinea infection during the first 11 months of the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Dermatology, Pediatrics
LITERATURE REFERENCES	<p>Alston SJ, Cohen BA, Braun M. Persistent and recurrent tinea corporis in children treated with combination antifungal/ corticosteroid agents. <i>Pediatrics</i>. 2003 Jan;111(1):201-3.</p> <p>Greenberg HL, Shwayder TA, Bieszk N, Fivenson DP. Clotrimazole/betamethasone dipropionate: a review of costs and complications in the treatment of common cutaneous fungal infections. <i>Pediatr Dermatol</i>. 2002 Jan-Feb;19(1):78-81.</p>

DRUG SAFETY MEASURES

HEDIS: PersistACE_ARB_K_SCr_12m	
MEASURE DESCRIPTION	This measure identifies patients age 18 or older who received at least a 180-day supply of ACE inhibitors or ARBs during the measurement year who had at least 1 serum potassium <i>and</i> either a serum creatinine or a blood urea nitrogen (BUN) test during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had at least 1 serum potassium <i>and</i> either a serum creatinine or a BUN test during the measurement year</p> <p><u>Denominator</u> = Patients who received >=180-day supply of ACE inhibitors or ARBs during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.

HEDIS: PersistentDigoxin_K Sc_12m	
MEASURE DESCRIPTION	This measure identifies patients age 18 or older who received at least a 180-day supply of digoxin during the measurement year who had at least 1 serum potassium <i>and</i> either a serum creatinine or a blood urea nitrogen (BUN) therapeutic monitoring test during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had at least 1 serum potassium <i>and</i> either a serum creatinine or a BUN test during the measurement year</p> <p><u>Denominator</u> = Patients prescribed \geq180-day supply of digoxin during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.



HEDIS: PersistDiuretics_K_SCr_12m	
MEASURE DESCRIPTION	This measure identifies patients age 18 or older who received at least a 180-day supply of diuretics during the measurement year who had at least 1 serum potassium <i>and</i> either a serum creatinine or a blood urea nitrogen (BUN) therapeutic monitoring test during the measurement year.
NUMERATOR/DENOMINATOR	<u>Numerator</u> = Patients in the denominator who had at least 1 serum potassium <i>and</i> either a serum creatinine or a BUN therapeutic monitoring test during the measurement year <u>Denominator</u> = Patients who received \geq 180-day supply of diuretics during the measurement year
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.

HEDIS: PersistAnticonvulsants_SerumDrug12m	
MEASURE DESCRIPTION	This measure identifies patients age 18 or older who received at least a 180-day supply of anticonvulsants during the measurement year who had at least 1 serum drug measurement (for the prescribed drug) during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had at least 1 serum drug measurement (for the prescribed drug) during the measurement year</p> <p><u>Denominator</u> = Patients prescribed \geq180-day supply of anticonvulsants during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Neurology
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.

Drug Safety 2: Clozapine_WBC needed	
MEASURE DESCRIPTION	This measure identifies the percentage of patients taking clozapine during the measurement year who have had a WBC test within 30 days of the earliest observed clozapine prescription
NUMERATOR/DENOMINATOR	<p><u>Numerator:</u> Patients in the denominator who have had a WBC test within 30 days of the earliest observed clozapine prescription</p> <p><u>Denominator:</u> Patients with ≥ 1 Rx claim for clozapine during the first 11 months of the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Psychiatry
LITERATURE REFERENCES	<p>Clozaril (clozapine) prescribing information. Novartis, Revised May 2005.</p> <p>Gerson, SL, Meltzer, H. Mechanisms of Clozapine-Induced Agranulocytosis. Drug Saf 1992; 7(Suppl 1):17.</p>

Lithium Annual Creatinine Test	
MEASURE DESCRIPTION	This measure identifies the percentage of patients taking lithium who have had at least one creatinine test after the earliest observed lithium prescription during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who received a serum creatinine test after the earliest observed lithium prescription during the measurement year</p> <p><u>Denominator</u> = Patients who received at least a 292-day supply of lithium during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Psychiatry
LITERATURE REFERENCES	<p>Freeman MP, Freeman SA. Lithium: clinical considerations in internal medicine. <i>Am J Med.</i> 2006 Jun;119(6):478-81.</p> <p>American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). <i>Am J Psychiatry.</i> 2002 Apr;159(4 Suppl):1-50</p>

Lithium Annual Thyroid Test	
MEASURE DESCRIPTION	This measure identifies the percentage of patients taking lithium who have had at least one thyroid function test after the earliest observed lithium prescription during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who received a thyroid function test after the earliest observed lithium prescription during the measurement year</p> <p><u>Denominator</u> = Patients who received at least a 292-day supply of lithium during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Psychiatry
LITERATURE REFERENCES	<p>Freeman MP, Freeman SA. Lithium: clinical considerations in internal medicine. Am J Med. 2006 Jun;119(6):478-81.</p> <p>American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002 Apr;159(4 Suppl):1-50</p>

Lithium Annual Lithium Test	
MEASURE DESCRIPTION	This measure identifies the percentage of patients taking lithium who have had at least one lithium level test after the earliest observed lithium prescription during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who received a lithium level test after the earliest observed lithium prescription during the measurement year</p> <p><u>Denominator</u> = Patients who received at least a 292-day supply of lithium during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Psychiatry
LITERATURE REFERENCES	American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002 Apr;159(4 Suppl):1-50



Prostate 1: BPH_anticholinergic	
MEASURE DESCRIPTION	This measure identifies the percentage of male patients with benign prostatic hyperplasia (BPH) without claims for anticholinergic medication in the last 6 months of the measurement year
NUMERATOR/DENOMINATOR	<u>Numerator</u> = Patients in the denominator without prescriptions for anticholinergic medications in the last 6 months of the measurement year <u>Denominator</u> = Men with history of BPH, but without history of TURP procedure or radical prostatectomy
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Urology
LITERATURE REFERENCES	Updating the Beers criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts. Arch Intern Med. 2003 Dec 8-22;163(22):2716-24

TZD Use_Annual LFT	
MEASURE DESCRIPTION	This measure identifies the percentage of patients who received at least a 292-day supply of thiazolidinediones (TZDs) during the measurement year who received a liver function test after the earliest observed TZD prescription.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who received a liver function test after the earliest observed TZD prescription during the measurement year</p> <p><u>Denominator</u> = Patients receiving at least a 292-day supply of a TZD during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Endocrinology
LITERATURE REFERENCES	<p>Marcy TR, Britton ML, Blevins SM. Second-generation thiazolidinediones and hepatotoxicity. <i>Ann Pharmacother</i>. 2004 Sep;38(9):1419-23.</p> <p>Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. <i>Diabetes Metab Res Rev</i>. 2002 Mar-Apr;18 Suppl 2:S23-9.</p>

ENDOCRINE MEASURES

Diabetes

HEDIS: Diabetes 2: DM_ HbA1c	
MEASURE DESCRIPTION	This measure identifies patients between 18 and 75 years old who have diabetes and who had at least 1 HbA1c test during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had at least 1 serum HbA1c test during the measurement year</p> <p><u>Denominator</u> = Patients with diabetes diagnosed during the measurement year or the year prior to the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Endocrinology
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.

HEDIS: Diabetes 115 DM_ LDL	
MEASURE DESCRIPTION	This measure identifies patients between 18 and 75 years old who have diabetes and who had an LDL-C level checked during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had an LDL-C level checked during the measurement year</p> <p><u>Denominator</u> = Patients with diabetes diagnosed during the measurement year or the year prior to the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Endocrinology, Cardiology
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.

Diabetes 121: DM HTN_ACEI	
MEASURE DESCRIPTION	This measure identifies patients with diabetes and hypertension or nephropathy who are taking an ACE inhibitor or ARB during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who have ≥ 1 Rx claim for an ACE inhibitor or an ARB during the measurement year.</p> <p><u>Denominator</u> = Patients with past medical history of diabetes plus hypertension or nephropathy diagnosed prior to the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology, Endocrinology
MEASURE CITATION	<p>Chobanian AV, et al. The Seventh Report of the Joint National Committee on prevention, detection, and evaluation and treatment of high blood pressure. NHLBI writing team. 2004. NIH Publication No. 04-5230</p> <p>American Diabetes Association. Standards of Medical Care in Diabetes--2008. 2008(31):S12-54.</p>

HEDIS: Diabetes 126 DM_ proteinurea	
MEASURE DESCRIPTION	This measure identifies patients between 18 and 75 years old who have diabetes and at least one test for microalbumin during the measurement year; or who had evidence of medical attention for existing nephropathy (diagnosis of nephropathy or documentation of microalbuminuria or albuminuria).
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = The number of patients from the denominator with at least one test for microalbumin during the measurement year; or who had evidence of medical attention for existing nephropathy (diagnosis of nephropathy or documentation of microalbuminuria or albuminuria)</p> <p><u>Denominator</u> = Patients with diabetes diagnosed during the measurement year or the year prior to the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Endocrinology
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.

New DM2_Metformin	
MEASURE DESCRIPTION	This measure identifies the percentage of patients newly diagnosed with diabetes type 2 who were treated with Metformin within three months following diagnosis, excluding patients who were immediately started on insulin therapy
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who have received at least 1 prescription claim for Metformin from diabetes diagnosis to 90 days after diagnosis</p> <p><u>Denominator</u> = Patients newly diagnosed with diabetes type 2 during the first 9 months of the measurement year, excluding those with insulin prescription claims</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Endocrinology
LITERATURE REFERENCES	Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006 Aug;29(8):1963-72.

Dyslipidemia

Dyslipidemia 55: New Lipid Rx_ lipid12wk	
MEASURE DESCRIPTION	This measure identifies patients who started lipid-lowering medication during the measurement year and had a lipid panel checked within 3 months after starting drug therapy.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had a serum lipid panel drawn within 3 months following start of lipid-lowering therapy</p> <p><u>Denominator</u> = Patients newly started on lipid-lowering therapy during the first 9 months of the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology, Endocrinology
MEASURE CITATION	National Heart, Lung, and Blood Institute, National Institutes of Health, US Department of Health and Human Services. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Bethesda (MD): U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung and Blood Institute; 2001

GASTROENTEROLOGY MEASURES

Misc Disease 2: Arthritis_ChronSAID_UlcerProphy	
MEASURE DESCRIPTION	This measure identifies patients with arthritis on chronic NSAIDs with an additional risk factor for GI bleed who are prescribed ulcer prophylaxis medication.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who received ulcer prophylaxis medication (PPI or misoprostol) during the measurement year</p> <p><u>Denominator</u> = Adult arthritis patients with chronic use of NSAIDs and a risk factor for GI bleeding (advanced age, ulcer disease, history of GI bleeding, or active use of steroid or anticoagulant medications)</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Gastroenterology, Rheumatology
MEASURE CITATION	Lanza FL. A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol. 1998;93(11):2037-46.

GI 1: IBD_Chronic Steroids_BMD test	
MEASURE DESCRIPTION	This measure identifies patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis) who have taken chronic steroids during the measurement year and have undergone a bone mineral density test within the past 2 years.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who have undergone a bone mineral density test within the past 2 years.</p> <p><u>Denominator</u> = Patients with inflammatory bowel disease (Crohn's disease, ulcerative colitis) who have taken chronic steroids (≥ 3 months) during the first half of the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Gastroenterology
MEASURE CITATION	Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. <i>Gastroenterology</i> . 2003;124(3):795-841.



GI 2: PUD_Comp_Hpylori_treatment	
MEASURE DESCRIPTION	This measure identifies the percentage of patients with a positive H. pylori test during the measurement year who have been treated for H. pylori within 1 month after the positive test result.
NUMERATOR/DENOMINATOR	<u>Numerator</u> = Patients in the denominator who have been treated for H. pylori within 1 month after the positive test result <u>Denominator</u> = Adult patients with a positive H. pylori test result during the measurement year
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Gastroenterology
LITERATURE REFERENCES	Talley NJ; American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology. 2005 Nov;129(5):1753-5. Peterson WL, Fendrick AM, Cave DR, et al. Helicobacter pylori-related disease: guidelines for testing and treatment. Arch Intern Med. 2000 May 8;160(9):1285-91.

GI 3: PUD_Comp_Hpylori_Test	
MEASURE DESCRIPTION	This measure identifies patients with a new diagnosis of ulcer who had an H. pylori test or GI endoscopy with biopsy 30 days prior to or 60 days after ulcer diagnosis, excluding those with an ER visit or hospitalization during that time.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had an H. pylori test or GI endoscopy with biopsy 30 days prior to or 60 days after their ulcer diagnosis</p> <p><u>Denominator</u> = Patients with a new diagnosis of ulcer during the measurement year, excluding those who had an ER visit or hospitalization 30 days prior to or 60 days after their ulcer diagnosis</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Gastroenterology
MEASURE CITATION	<p>Howden CW, Hunt, RH. American College of Gastroenterology Guidelines for the Management of Helicobacter Pylori Infection. Amer J Gastroenterol. 1998;93:12; 2330-8.</p> <p>Talley NJ; American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology. 2005;129(5):1753-5.</p>



Infectious Disease 1: HIV_Hep B screen	
MEASURE DESCRIPTION	This measure identifies the percentage of patients diagnosed with HIV/AIDS during the first 10 months of the measurement year who have had Hepatitis B virus (HBV) screening within 60 days after HIV diagnosis
NUMERATOR/DENOMINATOR	<u>Numerator</u> = Patients in the denominator who have received HBV screening within 60 days after HIV diagnosis <u>Denominator</u> = Patients diagnosed with HIV/AIDS during the first 10 months of the measurement year, without previous history of chronic HBV
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Infectious Disease
LITERATURE REFERENCES	Aberg JA, Gallant JE, Anderson J, et al; HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2004 Sep 1;39(5):609-29. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines 2006. MMWR 2006;Vol 55, No RR-11, p1-100.



Infectious Disease 2: HIV_Hep C screen	
MEASURE DESCRIPTION	This measure identifies the percentage of patients diagnosed with HIV/AIDS during the first 10 months of the measurement year who have had Hepatitis C virus (HCV) screening within 60 days after HIV diagnosis
NUMERATOR/DENOMINATOR	<u>Numerator</u> = Patients in the denominator who have received HCV screening within 60 days after diagnosis of HIV <u>Denominator</u> = Patients diagnosed with HIV/AIDS during the first 10 months of the measurement year, without previous history of chronic HCV
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Infectious Disease
LITERATURE REFERENCES	Aberg JA, Gallant JE, Anderson J, et al; HIV Medicine Association of the Infectious Diseases Society of America. Primary care guidelines for the management of persons infected with human immunodeficiency virus: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2004 Sep 1;39(5):609-29. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines 2006. MMWR 2006;Vol 55, No RR-11, p1-100.

Infectious Disease 3: HepCRx_HCV genotype test	
MEASURE DESCRIPTION	This measure identifies patients with Hepatitis C (HCV) who began HCV antiviral therapy during the measurement year and had HCV genotype testing prior to initiation of antiviral therapy.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had a HCV genotype test prior to initiation of antiviral therapy</p> <p><u>Denominator</u> = HCV patients who started HCV antiviral therapy during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Gastroenterology
MEASURE CITATION	<p>Dienstag, JL, McHutchison, JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology. 2006;130:225.</p> <p>Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4):1147-71.</p>

Infectious Disease 4: HepCRx_HCV_ViralLoad	
MEASURE DESCRIPTION	This measure identifies patients with Hepatitis C (HCV) who began HCV antiviral therapy during the measurement year and had HCV Viral Load testing prior to initiation of antiviral therapy.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had an HCV Viral Load test prior to initiation of antiviral therapy</p> <p><u>Denominator</u> = HCV patients who started HCV antiviral therapy during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Gastroenterology
MEASURE CITATION	<p>Dienstag, JL, McHutchison, JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology. 2006; 130:225.</p> <p>Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4):1147-71.</p>

HBV postvaccination titers	
MEASURE DESCRIPTION	This measure identifies the percentage of patients diagnosed with HIV/AIDS or those on chronic hemodialysis prior to the measurement year who received a test for postvaccination titers after their 3-shot course of Hepatitis B vaccine.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who have received Hepatitis B post-vaccination titers during the measurement year</p> <p><u>Denominator</u> = Patients previously diagnosed with HIV/AIDS or those on chronic hemodialysis prior to the measurement year who completed their 3rd shot of Hepatitis B vaccine during the first 6 months of the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Infectious Disease, Gastroenterology, Nephrology
LITERATURE REFERENCES	<p>Mast EE, Weinbaum CM, Fiore AE, et al; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006 Dec 8;55(RR-16):1-33</p> <p>Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007 Feb;45(2):507-39</p>

HEMATOLOGY MEASURES

Vascular 1: PE_antithrombotic	
MEASURE DESCRIPTION	This measure identifies patients with pulmonary embolism (PE) on anticoagulation for at least 3 months after the diagnosis.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had at least 3 months of anticoagulation after the event</p> <p><u>Denominator</u> = Patients diagnosed with a PE more than 3 months prior to the end of the measurement year, who do not have contraindications to warfarin therapy (contraindications include: evidence of eye surgery, GI bleed, aortic dissection, cerebral aneurysm, pericarditis, bacterial endocarditis, pregnancy, bleeding diatheses, or head trauma during or 1 year prior to the measurement year)</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Pulmonary Disease, Hematology & Oncology
MEASURE CITATION	Hirsh J, Guyatt G, Albers GW, Schünemann HJ. Proceedings of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: evidence-based guidelines. Chest. 2004;126(3 Suppl):172S-696S.

Vascular 2: LE DVT_antithrombotic	
MEASURE DESCRIPTION	This measure identifies patients with lower extremity deep vein thrombosis (DVT) on anticoagulation for at least 3 months after diagnosis.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had at least 3 months of anticoagulation after the event</p> <p><u>Denominator</u> = Patients diagnosed with a lower extremity DVT more than 3 months prior to the end of the measurement year, who do not have contraindications to warfarin therapy (contraindications include: evidence of eye surgery, GI bleed, aortic dissection, cerebral aneurysm, pericarditis, bacterial endocarditis, pregnancy, bleeding diatheses, or head trauma during or 1 year prior to the measurement year)</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Hematology & Oncology
MEASURE CITATION	Hirsh J, Guyatt G, Albers GW, Schünemann HJ. Proceedings of the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: evidence-based guidelines. Chest. 2004;126(3 Suppl):172S-696S.

MENTAL BEHAVIORAL HEALTH

HEDIS: Peds ADHD Rx 30d visit	
MEASURE DESCRIPTION	This measure identifies patients age 6 to 12 years with an ambulatory prescription dispensed for attention-deficit/hyperactivity disorder (ADHD) medication who had one follow-up visit during the 30-day initiation period.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients from the denominator with one ambulatory follow-up visit within 30 days after the Index Prescription Start Date.</p> <p><u>Denominator</u> = Patients age 6 to 12 years as of the Index Prescription Episode Start Date who were dispensed an attention deficit/hyperactivity disorder (ADHD) medication during the 12-month Intake Period (Intake Period occurs before the last 8-months of the measurement year). Measure excludes patients with any claims history for narcolepsy.</p>
APPLICABLE SPECIALTIES	Family Practice, Pediatrics, Psychiatry, General Practice
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Vol 2. Washington, DC: National Committee for Quality Assurance; 2007.

HEDIS: Peds ADHD Rx 2Visits 31-300d	
MEASURE DESCRIPTION	This measure identifies patients age 6 to 12 years with an ambulatory prescription dispensed for attention-deficit/hyperactivity disorder (ADHD) medication who had one follow-up visit during the 30-day initiation period and at least 2 follow-up visits with a practitioner within 270 days after the Initiation Phase ended.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients from the denominator with one ambulatory follow-up visit with a practitioner with prescribing authority within 30 days after the Index Prescription Start Date AND at least 2 follow-up visits (one can be via telephone) from 31 through 300 days after the Index Prescription Start Date.</p> <p><u>Denominator</u> = Patients age 6 to 12 years as of the Index Prescription Episode Start Date who were dispensed an attention deficit/hyperactivity disorder (ADHD) medication during the 12-month Intake Period prior to the last 10 months of the measurement year. Measure excludes patients with any claims history for narcolepsy</p>
APPLICABLE SPECIALTIES	Family Practice, Pediatrics, Psychiatry, General Practice
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Vol 2. Washington, DC: National Committee for Quality Assurance; 2007.

NEUROLOGY

Headache 21: CHD_MigraineRxInteraction	
MEASURE DESCRIPTION	This measure identifies patients with CHD who are not taking a triptan or ergot derivative.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who are not taking a triptan or an ergot derivative</p> <p><u>Denominator</u> = Patients with CHD diagnosed prior to the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Cardiology, Neurology
MEASURE CITATION	<p>Dodick D, Lipton RB, et al. Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT_{1B/1D} Agonists) in the Acute Treatment of Migraine. <i>J Head Face Pain</i>. 2004;44(5):414-425.</p> <p>Scher AI, Terwindt GM. Cardiovascular risk factors and migraine. <i>Neurology</i>. 2005;64:614-620.</p> <p>Snow V, Weiss K, Wall EM, Mottur-Pilson C; American Academy of Family Physicians; American College of Physicians-American Society of Internal Medicine. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. <i>Ann Intern Med</i>. 2002;137(10):840-9.</p>

New Dementia_B12 TSH	
MEASURE DESCRIPTION	This measure identifies the percentage of patients at least 50 years old newly diagnosed with dementia during the first 9 months of the measurement year who have received TSH and B12 testing from time of dementia diagnosis through the end of the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who have received TSH and B12 lab testing from time of dementia diagnosis through the end of the measurement year</p> <p><u>Denominator</u> = Patients at least 50 years old newly diagnosed with dementia during the first 9 months of the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Neurology
LITERATURE REFERENCES	<p>Rabins PV, Lyketsos CG, Steele CD. Practical dementia care. New York: Oxford University Press, 1999:46.</p> <p>Santacruz KS, Swagerty D. Early diagnosis of dementia. Am Fam Physician. 2001 Feb 15;63(4):703-13, 717-8.</p>

OPHTHALMOLOGY

HEDIS: Glaucoma Screening	
MEASURE DESCRIPTION	This measure identifies the percentage of patients aged 65 years and older without a prior diagnosis of glaucoma or glaucoma suspect, who received a glaucoma eye exam in the last two years by an eye-care professional for early identification of persons with glaucomatous conditions.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who have received at least one eye exam for glaucoma by an eye care professional (ophthalmologist or optometrist) during the measurement year or the year prior to the measurement year</p> <p><u>Denominator</u> = Members aged 67 years and older as of December 31 of the measurement year, excluding those with prior diagnosis of glaucoma or glaucoma suspect</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Ophthalmology
LITERATURE REFERENCES	<p>National Committee for Quality Assurance. HEDIS 2007. Vol 2. Washington, DC: National Committee for Quality Assurance; 2006.</p> <p>American Academy of Ophthalmology. Primary Open-Angle Glaucoma, Preferred Practice Pattern. San Francisco: American Academy of Ophthalmology, 2005.</p>

PostOp Comp_Cataract Surgery	
MEASURE DESCRIPTION	This measure identifies adult patients with a diagnosis of uncomplicated cataract who had cataract surgery during the measurement year and did not have any of a specified list of surgical procedures in the 30 days following cataract surgery, which would indicate the occurrence of any of the following major complications: retained nuclear fragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment, or wound dehiscence.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients from the denominator who did not have one or more specified operative procedures for any of the following major complications within 30 days following cataract surgery: retained nuclear fragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment, or wound dehiscence</p> <p><u>Denominator</u> = Patients ≥ 18 years of age who had cataract surgery during the measurement year and no significant pre-operative ocular conditions impacting the surgical complication rate</p>
APPLICABLE SPECIALTIES	Ophthalmology
MEASURE CITATION	Eye Care Physician Performance Measurement Set. American Academy of Ophthalmology/Physician Consortium for Performance Improvement®/ National Committee for Quality Assurance. October 2007.

OTOLARYNGOLOGY

Acute Otitis Externa_Systemic Abx	
MEASURE DESCRIPTION	This measure identifies patients age 2 years and older with a diagnosis of acute otitis externa (AOE) who were <u>not</u> prescribed systemic antimicrobial therapy within 7 days after the AOE episode.
NUMERATOR/DENOMINATOR	<u>Numerator</u> = Patients from the denominator who did not receive systemic antimicrobial therapy within 7 days after the AOE episode <u>Denominator</u> = All patients age 2 years and older with a diagnosis of AOE during the measurement year
APPLICABLE SPECIALTIES	Family Practice, Pediatrics, Internal Medicine, Otolaryngology, General Practice
MEASURE CITATION	Acute Otitis Externa (AOE)/Otitis Media with Effusion (OME) Physician Performance Measurement Set. American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS) Foundation/Physician Consortium for Performance Improvement. March 2007

Otitis Media Effusion_Systemic Abx	
MEASURE DESCRIPTION	This measure identifies patients age 2 months through 12 years with a diagnosis of otitis media with effusion (OME) who were not prescribed systemic antimicrobials within 7 days after the OME episode.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients from the denominator who did not receive systemic antimicrobial therapy within 7 days after the OME episode</p> <p><u>Denominator</u> = All patients age 2 months through 12 years with a diagnosis of OME during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, Pediatrics, Otolaryngology, General Practice
MEASURE CITATION	Acute Otitis Externa (AOE)/Otitis Media with Effusion (OME) Physician Performance Measurement Set. American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS) Foundation/Physician Consortium for Performance Improvement. March 2007

Tympanostomy Tube Hearing Test	
MEASURE DESCRIPTION	This measure identifies patients age 2 months through 12 years with OME who received tympanostomy tube(s) insertion during the measurement year and had a hearing test performed within 6 months prior to tube placement.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients from the denominator who underwent hearing testing within 6 months prior to the tube(s) insertion</p> <p><u>Denominator</u> = Patients age 2 months through 12 years old with OME who received tympanostomy tube(s) insertion during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, Pediatrics, Otolaryngology, General Practice
MEASURE CITATION	Acute Otitis Externa (AOE)/Otitis Media with Effusion (OME) Physician Performance Measurement Set. American Academy of Otolaryngology – Head and Neck Surgery (AAO-HNS) Foundation/Physician Consortium for Performance Improvement. March 2007.

PRENATAL CARE MEASURES

Prenatal Care 12: Pregnancy_HIV	
MEASURE DESCRIPTION	This measure identifies women who had an HIV test during pregnancy.
NUMERATOR/DENOMINATOR	<u>Numerator</u> = Patients in the denominator who had HIV testing up to 4 months prior to the first observed pregnancy claim to the end of the measurement year <u>Denominator</u> = Female members with pregnancy onset date during the first 8 months of the measurement year, without prior history of HIV/AIDS
APPLICABLE SPECIALTIES	Family Practice, General Practice, Obstetrics and Gynecology
MEASURE CITATION	Evidence-Based Prenatal Care: Parts I & II, American Academy of Family Physicians. Am Fam Phys. 2005;71(7,8):1307-1316, 1555-1560. Centers for Disease Control and Prevention; Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006;55(RR-11):1-94.

Prenatal Care 11: Pregnancy Screen_ Hep B	
MEASURE DESCRIPTION	This measure identifies pregnant women who had a test for Hepatitis B virus (HBV) during pregnancy.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had a serologic test for HBV up to 4 months prior to the first observed pregnancy claim to the end of the measurement year</p> <p><u>Denominator</u> = Female members with pregnancy onset date during the first 8 months of the measurement year, without prior history of chronic HBV</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Obstetrics & Gynecology
MEASURE CITATION	<p>Evidence-Based Prenatal Care: Parts I & II, American Academy of Family Physicians. Am Fam Phys. 2005;71(7,8):1307-1316, 1555-1560.</p> <p>Centers for Disease Control and Prevention; Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep. 2006;55(RR-11):1-94.</p> <p>Advisory Committee on Immunization Practice, American Academy of Family Physicians. General recommendations on immunization. MMWR Recomm Rep. 2002;51(RR-2):1-36.</p>

Prenatal Care 38: Diabetes_ Oral agents	
MEASURE DESCRIPTION	This measure identifies pregnant women with diabetes who are not taking an oral hypoglycemic agent.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who are not taking an oral hypoglycemic agent</p> <p><u>Denominator</u> = Pregnant women with a diagnosis of non-gestational diabetes prior to pregnancy</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Obstetrics & Gynecology, Endocrinology
MEASURE CITATION	<p>American Diabetes Association. Standards of Medical Care in Diabetes--2008. 2008;31:S12-54.</p> <p>American College of Obstetrics and Gynecology: Pregestational diabetes mellitus. ACOG Practice Bulletin – No. 60. Obstet Gynecol. 2005;105:675–685.</p>

PREVENTIVE HEALTH MEASURES

Women's Health

Preventive Care 26: High-risk_Pap Smear	
MEASURE DESCRIPTION	This measure identifies women age 12 to 65 diagnosed with cervical dysplasia, cervical carcinoma-in-situ, or HIV/AIDS prior to the measurement year, and who still have a cervix, who had a cervical CA screen during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had a cervical CA screen during the measurement year</p> <p><u>Denominator</u> = Women who are 12-65 years of age who have a diagnosis of cervical dysplasia, cervical carcinoma-in-situ, or HIV/AIDS diagnosed prior to the measurement year, and who still have a cervix (excludes women with a hysterectomy)</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Obstetrics & Gynecology, Pediatrics
MEASURE CITATION	<p>U.S. Preventive Services Task Force. Guide to Clinical Preventive Services: 2007. AHRQ Publication No. 07-05100, September 2007. Agency for Healthcare Research and Quality, Rockville, MD</p> <p>American College of Obstetricians and Gynecologists. Guidelines for Women's Health Care. 2nd ed. Washington, DC: ACOG. 2002;121-134, 140-141.</p>

Osteo 1: Women 66-67y_BMDTest	
MEASURE DESCRIPTION	This measure identifies women, without a prior history for osteoporosis, age 66 to 67 years old who had a bone mineral density test (BMD) within the past 2 years.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had a BMD test within the past 2 years</p> <p><u>Denominator</u> = Women between age 66 and 67, without history of osteoporosis or osteoporosis medications</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Obstetrics and Gynecology
MEASURE CITATION	U.S. Preventive Services Task Force. Guide to Clinical Preventive Services: 2007. AHRQ Publication No. 07-05100, September 2007. Agency for Healthcare Research and Quality, Rockville, MD

HEDIS: CervCA_screen	
MEASURE DESCRIPTION	This measure identifies women age 21 to 64 who had at least 1 Pap test during the measurement year or during the 2 years prior to the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had 1 or more Pap tests during the measurement year or during the 2 years prior to the measurement year</p> <p><u>Denominator</u> = Women who are 24-64 years of age as of the end of the measurement year who have a cervix (excludes women with a hysterectomy)</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Obstetrics & Gynecology
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.

HEDIS: Osteoporosis_Mgmt_Fx	
MEASURE DESCRIPTION	This measure identifies women age 67 or older who suffered a bone fracture and had either a bone mineral density (BMD) test or a prescription for a drug to treat or prevent osteoporosis during the 6 months after the date of fracture.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had either a bone mineral density test or a prescription for a drug to treat or prevent osteoporosis in the 6 months after the date of fracture</p> <p><u>Denominator</u> = Women who are 67 years or older who suffered a bone fracture during the 6 months prior to the measurement year or during the first 6 months of the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Obstetrics & Gynecology, Rheumatology, Orthopedic Surgery
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.



HEDIS: Chlamydia_screen	
MEASURE DESCRIPTION	This measure identifies women age 16 to 25 identified as sexually active who had at least 1 Chlamydia test during the measurement year.
NUMERATOR/DENOMINATOR	<u>Numerator</u> = Patients in the denominator who had 1 or more tests for Chlamydia during the measurement year <u>Denominator</u> = Females who are 16-25 years of age who were identified as sexually active (based on codes from claims during the measurement year that indicate pregnancy or abortion, as well as Rx claims for contraception)
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Obstetrics & Gynecology, Pediatrics
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.

BrCA 8: BrCA_mammogram	
MEASURE DESCRIPTION	This measure identifies women with breast cancer who had an annual follow-up mammogram.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had an annual follow-up mammogram during the measurement year</p> <p><u>Denominator</u> = Patients who have had breast cancer (excluding women with bilateral mastectomy)</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, General Surgery, Obstetrics & Gynecology, Hematology & Oncology
MEASURE CITATION	<p>NCCN Clinical Practice Guidelines in Oncology for Breast Cancer. National Comprehensive Cancer Network, Vol 2, 2006.</p> <p>Khatcheressian JL, Wolff AC, Smith TJ, et al, American Society of Clinical Oncology. American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol. 2006;1;24(31):5091-7.</p>



HEDIS: BrCA_Screen	
MEASURE DESCRIPTION	This measure identifies women age 42 to 69 as of Dec 31 st of the measurement year who had a mammogram during the measurement year or during the year prior to the measurement year.
NUMERATOR/DENOMINATOR	<u>Numerator</u> = Patients in the denominator who had a mammogram during the measurement year or during year prior to the measurement year <u>Denominator</u> = Women who are 42-69 years of age by Dec 31 st of the measurement year
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Obstetrics & Gynecology
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.

Well Child Visits

Preventative Health 278: Age 0-6mo_ 4 visits	
MEASURE DESCRIPTION	This measure identifies infants who had at least 4 office visits during the first 6 months of life (6-month observation period).
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had at least 4 office visits during the first 6 months of life</p> <p><u>Denominator</u> = Children born during the measurement year and who are at least 6 months old as of the end of the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Pediatrics
MEASURE CITATION	<p>American Academy of Pediatrics, Committee on Practice and Ambulatory Medicine. Recommendations for preventive pediatric health care. Pediatrics. 2000;105:645-6.</p> <p>Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years - United States, 2007. MMWR. 2006;55(51&52):Q1-Q4.</p>

Preventative Health 279: Age 6-12mo_ 3 visits	
MEASURE DESCRIPTION	This measure identifies infants who had at least 3 office visits between age 6 and 12 months (6-month observation period).
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had at least 3 office visits between the ages of 6 and 12 months of age</p> <p><u>Denominator</u> = Infants who are between 12 to 18 months of age as of the end of the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Pediatrics
MEASURE CITATION	<p>American Academy of Pediatrics, Committee on Practice and Ambulatory Medicine. Recommendations for preventive pediatric health care. Pediatrics. 2000;105:645-6.</p> <p>Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years - United States, 2007. MMWR. 2006;55(51&52):Q1-Q4.</p>

Preventative Health 280: Age 12-24m_3 visits	
MEASURE DESCRIPTION	This measure identifies children who had at least 3 office visits between age 12 and 24 months (1-year observation period).
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had at least 3 office visits from age 12 months to 24 months</p> <p><u>Denominator</u> = Children between age 2 and 2.5 as of the end of the measurement year.</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Pediatrics
MEASURE CITATION	<p>American Academy of Pediatrics, Committee on Practice and Ambulatory Medicine. Recommendations for preventive pediatric health care. Pediatrics. 2000;105:645-6.</p> <p>Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years - United States, 2007. MMWR. 2006;55(51&52):Q1-Q4.</p>

Preventative Health 281: Age 2-6yrs_1 visit	
MEASURE DESCRIPTION	This measure identifies children between age 2 and 6 who had at least 1 check-up during the measurement year (1-year observation period).
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had at least 1 check-up during the measurement year</p> <p><u>Denominator</u> = Children between age 3 and 6 as of the end of the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Pediatrics
MEASURE CITATION	<p>American Academy of Pediatrics, Committee on Practice and Ambulatory Medicine. Recommendations for Preventive pediatric health care. Pediatrics. 2000;105:645-6.</p> <p>Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years - United States, 2007. MMWR. 2006;55(51&52):Q1-Q4.</p>

Preventative Health 282: Age 7-18yrs_1 visit	
MEASURE DESCRIPTION	This measure identifies children between age 7 and 18 who had at least 1 check-up during the past 2 years (2-year observation period).
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had at least 1 office visit during the past 2 years</p> <p><u>Denominator</u> = Children between age 9 and 18 as of the end of the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Pediatrics
MEASURE CITATION	<p>American Academy of Pediatrics, Committee on Practice and Ambulatory Medicine. Recommendations for Preventive pediatric health care. Pediatrics. 2000;105:645-6.</p> <p>Centers for Disease Control and Prevention. Recommended immunization schedules for persons aged 0-18 years - United States, 2007. MMWR. 2006;55(51&52):Q1-Q4.</p>

PULMONARY MEASURES

Asthma

Mod-severe Asthma_ B2 agonist	
MEASURE DESCRIPTION	This measure identifies patients age 5 or older with persistent asthma present during the first 6 months of the measurement year who have filled a prescription for a short-term beta-2 agonist inhaler after diagnosis.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who received a short-term beta-2 agonist inhaler medication anytime in the last six months of the measurement year</p> <p><u>Denominator</u> = Patients with persistent asthma activity (based on NCQA/HEDIS definition) during the first 6 months of the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Pediatrics, Pediatric Allergy, Pediatric Pulmonology, Pulmonary Disease, Allergy & Immunology
MEASURE CITATION	<p>Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute (NHLBI). Global strategy for asthma management and prevention. Bethesda (MD); Revised 2006.</p> <p>National Asthma Education and Prevention Program Expert Panel Report: guidelines for the diagnosis and management of asthma update on selected topics-2002. J Allergy Clin Immunol. 2002;110(5 pt 2):S141-219.</p>

HEDIS_Appropriate Meds for Asthma	
MEASURE DESCRIPTION	This measure identifies patients age 5 to 56 during the measurement year who have persistent asthma and who were appropriately prescribed medication during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who have at least 1 claim for an asthma controller medication</p> <p><u>Denominator</u> = Patients who meet HEDIS criteria for persistent asthma during or prior to the measurement year with pharmacy benefits during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Pediatrics, Pediatric Allergy, Pediatric Pulmonology, Pulmonary Disease, Allergy & Immunology
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.

COPD

Misc Diseases 236: COPD_Asthma_B2 Overuse	
MEASURE DESCRIPTION	This measure identifies patients with asthma or COPD who are not overusing beta-2 agonists.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who are not overusing beta-2 agonist medications based on Rx claims during the past 90 days</p> <p><u>Denominator</u> = Patients with asthma or COPD who are being treated with a beta-2 agonist</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Pediatrics, Pulmonary Disease, Pediatric Pulmonology
MEASURE CITATION	<p>Global Initiative for Asthma (GINA), National Heart, Lung and Blood Institute (NHLBI). Global strategy for asthma management and prevention. Bethesda (MD); Revised 2006.</p> <p>National Asthma Education and Prevention Program Expert Panel Report: guidelines for the diagnosis and management of asthma update on selected topics-2002. J Allergy Clin Immunol. 2002;110(5 pt 2):S141-219.</p> <p>Global Initiative for Chronic Obstructive Lung Disease (GOLD), World Health Organization (WHO), National Heart, Lung and Blood Institute (NHLBI). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda (MD); 2005.</p>

Other Respiratory

HEDIS: Pharyngitis Appropriate Testing	
MEASURE DESCRIPTION	This measure identifies children 2–18 years of age who were diagnosed with pharyngitis prior to or during the measurement year, dispensed an antibiotic, and had a test for group A streptococcus for the episode.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who had a test for group A streptococcus (strep) for the episode of pharyngitis</p> <p><u>Denominator</u> = Children age 2 to 18 who were diagnosed with pharyngitis and dispensed an antibiotic within 6 months prior to the measurement year or during the first 6 months of the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Pediatrics
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.

HEDIS: URI Appropriate Rx	
MEASURE DESCRIPTION	This measure identifies children age 3 months to 18 years who were diagnosed with an upper respiratory infection (URI) who did not receive an antibiotic prescription within 3 days after diagnosis.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who did not receive an antibiotic prescription within 3 days after the diagnosis</p> <p><u>Denominator</u> = Children age 3 months old as of 18 months prior to the end of the measurement year to 18 years old 6 months prior to the end of the measurement year who were diagnosed with URI between 545 and 180 days prior to the end of the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Pediatrics
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.

HEDIS: Acute Bronchitis Adults_Avoid Abx	
MEASURE DESCRIPTION	This measure identifies adults age 18 to 64 years with a diagnosis of acute bronchitis who were not dispensed an antibiotic prescription on or within three days after the Index Episode Start Date.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients from the denominator who were not dispensed a prescription for antibiotic medication on or within three days after the Index Episode Start Date</p> <p><u>Denominator</u> = Patients >=18 years of age at the start of the year prior to the measurement year to <64 years of age by the end of the measurement year, with a Negative Medication History, a Negative Comorbid Condition History and a Negative Competing Diagnosis, who had an outpatient or emergency department (ED) visit with any diagnosis of acute bronchitis during the Intake Period.</p>
APPLICABLE SPECIALTIES	Family Practice, Internal Medicine, Pulmonology, General Practice
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.

RHEUMATOLOGY

HEDIS: DMARDs in RA	
MEASURE DESCRIPTION	This measure identifies patients with a diagnosis of RA and who were dispensed at least one ambulatory prescription for a disease-modifying anti-rheumatic drug (DMARD) during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who were dispensed at least one ambulatory prescription for a disease-modifying anti-rheumatic drug (DMARD) during the measurement year</p> <p><u>Denominator</u> = Patients ≥ 18 years old to < 65 years old of age with 2 face-to-face physician encounters with different dates of service in an outpatient or non-acute inpatient setting during the first 11 months of the measurement year with any diagnosis of rheumatoid arthritis (RA)</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Rheumatology
MEASURE CITATION	National Committee for Quality Assurance. HEDIS 2008. Washington, DC: National Committee for Quality Assurance. Technical Specifications Vol 2, 2007.

New RA_ESR or CRP in 3mos	
MEASURE DESCRIPTION	This measure identifies adult patients newly diagnosed with rheumatoid arthritis during the first 8 months of the measurement year who received erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP) lab tests either 4 months (3 months + 1-month grace period) before or after the initial diagnosis.
NUMERATOR/DENOMINATOR	<u>Numerator</u> = Patients in the denominator who had an ESR or CRP lab test either 4 months before or after the initial rheumatoid arthritis diagnosis date <u>Denominator</u> = Patients >=18 years old newly diagnosed with rheumatoid arthritis during the first 8 months of the measurement year
APPLICABLE SPECIALTIES	Family Practice, Internal Medicine, Rheumatology
MEASURE CITATION	American College of Rheumatology's Starter Set of Measures for Quality in the Care for Rheumatic and Musculoskeletal Diseases, February 2006. American College of Rheumatology.

RA_New DMARDs Baseline CBC	
MEASURE DESCRIPTION	This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline complete blood count (CBC) testing within 90 days before to 14 days after the new start of sulfasalazine, methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, oral gold, cyclosporine, or cyclophosphamide during the measurement year.
NUMERATOR/DENOMINATOR	<u>Numerator</u> = Patients in the denominator who received CBC testing within 90 days before to 14 days after the new start of 'DMARD needing baseline CBC' <u>Denominator</u> = Patients >=18 years old with a history of rheumatoid arthritis and a new start of 'DMARD needing baseline CBC' (specifically, sulfasalazine, methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, oral gold, cyclosporine, or cyclophosphamide) during the measurement year
APPLICABLE SPECIALTIES	Family Practice, Internal Medicine, Rheumatology
MEASURE CITATION	American College of Rheumatology's Starter Set of Measures for Quality in the Care for Rheumatic and Musculoskeletal Diseases, February 2006. American College of Rheumatology.

RA_New DMARDs Baseline Scr	
MEASURE DESCRIPTION	This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline serum creatinine testing within 90 days before to 14 days after a new start of methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, cyclosporine, or cyclophosphamide during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who received serum creatinine testing within 90 days before to 14 days after the new start of ‘DMARD needing baseline SCr’</p> <p><u>Denominator</u> = Patients >=18 years old with a history of rheumatoid arthritis and a new start of ‘DMARD needing baseline SCr’ (specifically, methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, cyclosporine, or cyclophosphamide) during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, Internal Medicine, Rheumatology
MEASURE CITATION	American College of Rheumatology’s Starter Set of Measures for Quality in the Care for Rheumatic and Musculoskeletal Diseases, February 2006. American College of Rheumatology.

RA_New DMARDs Baseline AST or ALT	
MEASURE DESCRIPTION	This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline AST or ALT testing within 90 days before to 14 days after a new start of sulfasalazine, methotrexate, leflunomide, azathioprine, cyclosporine or cyclophosphamide during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who received serum creatinine testing within 90 days before to 14 days after the new start of ‘DMARD needing baseline AST or ALT’</p> <p><u>Denominator</u> = Patients >=18 years old with a history of rheumatoid arthritis and a new start of ‘DMARD needing baseline AST or ALT’ (specifically, sulfasalazine, methotrexate, leflunomide, azathioprine, cyclosporine or cyclophosphamide) during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, Internal Medicine, Rheumatology
MEASURE CITATION	American College of Rheumatology’s Starter Set of Measures for Quality in the Care for Rheumatic and Musculoskeletal Diseases, February 2006. American College of Rheumatology.

RA_New DMARD Baseline CXR	
MEASURE DESCRIPTION	This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received baseline chest imaging within 1 year before to 14 days after the new start of selected DMARDs (methotrexate, etanercept, kineret, infliximab, or adalimumab) during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who received a chest x-ray (CXR) or chest computed tomography (CT) within 1 year before to 14 days after the new start of selected DMARDs</p> <p><u>Denominator</u> = Patients >=18 years old with a history of rheumatoid arthritis and a new start of selected DMARDs (methotrexate, etanercept, kineret, infliximab, or adalimumab) during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, Internal Medicine, Rheumatology
MEASURE CITATION	American College of Rheumatology's Starter Set of Measures for Quality in the Care for Rheumatic and Musculoskeletal Diseases, February 2006. American College of Rheumatology.

Hydroxychloroquine Use_Annual Eye Exam	
MEASURE DESCRIPTION	This measure identifies the percentage of patients with Rheumatoid Disease who received hydroxychloroquine during the measurement year and had a fundoscopic examination during the measurement year or in the year prior to the measurement year
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who have undergone a fundoscopic exam by an eye care professional during the measurement year or in the year prior to the measurement year</p> <p><u>Denominator</u> = Patients with a diagnose of rheumatoid disease who were prescribed at least a 292-day supply of hydroxychloroquine during the measurement year, excluding those with a prior history of blindness</p>
APPLICABLE SPECIALTIES	Family Practice, General Practice, Internal Medicine, Ophthalmology, Rheumatology
LITERATURE REFERENCES	<p>American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum. 2002 Feb;46(2):328-46.</p> <p>Marmor MF. New American Academy of Ophthalmology recommendations on screening for hydroxychloroquine retinopathy. Arthritis Rheum. 2003 Jun;48(6):1764..</p>

Methotrexate_CBC q12 weeks	
MEASURE DESCRIPTION	This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a CBC test within 120 days (3 months + 1 month grace period) following the earliest observed methotrexate prescription claim.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who received a CBC test within 120 days following the earliest observed methotrexate prescription claim</p> <p><u>Denominator</u> = Patients >=18 years old with rheumatoid arthritis who have received at least a 6-month supply of oral methotrexate during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, Internal Medicine, Rheumatology
MEASURE CITATION	American College of Rheumatology 2008 Recommendations for the use of Nonbiologic and Biologic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. Arthritis Rheum. 2008;59(6):762-784.

Methotrexate_Cr q12 weeks	
MEASURE DESCRIPTION	This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a serum creatinine test in the 120 days (3 months + 1 month grace period) after the earliest observed methotrexate prescription claim.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who received a serum creatinine test in the 120 days following the earliest observed methotrexate prescription claim</p> <p><u>Denominator</u> = Patients ≥ 18 years old with rheumatoid arthritis who have received at least a 6-month supply of oral methotrexate during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, Internal Medicine, Rheumatology
MEASURE CITATION	American College of Rheumatology 2008 Recommendations for the use of Nonbiologic and Biologic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. <i>Arthritis Rheum.</i> 2008;59(6):762-784.

Methotrexate_LFT q12wks	
MEASURE DESCRIPTION	This measure identifies adult patients with rheumatoid arthritis who were prescribed at least a 6-month supply of methotrexate during the measurement year and received a liver function test in the 120 days (3 months + 1 month grace period) following the earliest observed methotrexate prescription claim.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who received a liver function test in the 120 days following the earliest observed methotrexate prescription claim</p> <p><u>Denominator</u> = Patients ≥ 18 years old with rheumatoid arthritis who have received at least a 6-month supply of oral methotrexate during the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, Internal Medicine, Rheumatology
MEASURE CITATION	American College of Rheumatology 2008 Recommendations for the use of Nonbiologic and Biologic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis. <i>Arthritis Rheum.</i> 2008;59(6):762-784.

Osteoporosis Rx Therapy	
MEASURE DESCRIPTION	This measure identifies patients age 50 years or older with a diagnosis of osteoporosis who were prescribed pharmacologic therapy during the measurement year.
NUMERATOR/DENOMINATOR	<p><u>Numerator</u> = Patients in the denominator who received osteoporosis drug therapy during the measurement year</p> <p><u>Denominator</u> = Patients >=50 years old at the start of the measurement year who were diagnosed with osteoporosis prior to the measurement year</p>
APPLICABLE SPECIALTIES	Family Practice, Internal Medicine, Rheumatology, Obstetric-Gynecology
MEASURE CITATION	Osteoporosis Physician Performance Measurement Set. American Academy of Family Physicians/American Academy of Orthopaedic Surgeons/American Association of Clinical Endocrinologists/American College of Rheumatology/The Endocrine Society/Physician Consortium for Performance Improvement. October 2006.